WEBULL
WebtradeDownload

Veeva Systems (VEEV) Stock Rallies As Profit Growth Sharpens Execution Story

Simply Wall St · 1d ago

Veeva Systems just put a 15.2% one day surge in front of investors and asked a blunt question: Is the long term thesis on quality, sticky life sciences software finally lining up with the quarterly print? Coming into the release, the stock already carried a rich 45.2x trailing P/E and a reputation for premium pricing on growth.

The headline this quarter is earnings power. Fiscal Q2 basic earnings per share landed at US$1.68 on revenue of US$927.96m. Net income excluding extra items reached US$273.43m. The market reaction indicates that investors were willing to pay up for that profit story.

Impressed by the earnings power Veeva Systems just demonstrated but hesitant about paying a 45.2x trailing P/E for the stock? Explore our screener of quality stocks that combine premium pricing with strong profitability using the 46 high quality undervalued stocks

Q2 2027 Earnings Summary

  • Revenue (Q2 2027 vs Q2 2026): US$927.96m vs. US$789.08m (up about 17.6%)
  • Net Income Excluding Extra Items (Q2 2027 vs Q2 2026): US$273.43m vs. US$200.31m (up about 36.5%)
  • Basic EPS (Q2 2027 vs Q2 2026): US$1.68 vs. US$1.23 (up about 37.4%)
  • Trailing 12 Month Net Profit Margin (FY to Q2 2027 vs prior year): 29.3% vs. 27.3% (margin expanded by about 2 percentage points)

Prefer clear visuals instead of another wall of earnings tables and footnotes? See Veeva Systems' full financial picture, with a focus on its valuation, in the easy to scan company report for Veeva Systems.

NYSE:VEEV Trailing 12-Month Earnings & Revenue History as at Aug 2026
NYSE:VEEV Trailing 12-Month Earnings & Revenue History as at Aug 2026

Evaluating Veeva Systems’ Execution Against Its Growth Story

The bullish view on Veeva Systems hinges on two things. First, that Vault CRM can replace legacy CRM footprints at large pharma. Second, that AI agents like Falcon and Falcon MLR will become a meaningful fourth pillar alongside software, data and services.

This quarter gave tangible milestones for both claims. On CRM, Veeva highlighted global Vault CRM commitments from Eli Lilly and Regeneron and added multiple new top 20 pharma customers, with more than 150 Vault CRM implementations now live. That directly supports the idea that CRM revenue can persist as customers migrate rather than churn. On AI, Falcon and Vault AI are already in early commercialization, and Falcon MLR is live following the Copli deal, targeting up to a 70% cut in manual MLR workload. Paired with an 18% revenue increase and raised FY27 guidance, these developments show the thesis progressing from slideware toward execution.

Access the detailed multi year models behind Veeva Systems and see where the consensus starts to break. Reveal what the street is secretly modeling for the next fiscal years in the full analyst estimates for Veeva Systems

Veeva Bear Case: CRM and AI Milestones Still Unproven

The bearish view on Veeva Systems is that CRM is maturing, AI may not become a durable revenue engine, and revenue quality could lean too heavily on services or acquisitions. This quarter’s record CRM quarter and new global Vault CRM wins at Eli Lilly and Regeneron run directly against fears of immediate CRM erosion. However, bears can point out that Veeva still needs more visible evidence that these migrations convert to long-run share stability across all top pharma.

On AI, Falcon, Falcon MLR, and Vault AI are in early commercialization. Management itself calls product readiness and controlled rollout the rate limiter. That means the concern that AI takes longer to matter is not disproved. Revenue mix worries look less supported given strong commercial subscriptions, but the lack of disclosed AI-specific revenue or margin contribution keeps the question of high-quality, AI-driven growth open rather than settled.

With Veeva Systems now trading on a 45.2x P/E and investors paying up for profit margins near 30%, the real question is whether the balance sheet supports this premium. Check the full liquidity, cash, and debt profile in the financial health analysis of Veeva Systems stock.

Stay Ahead With Veeva Systems Insights

If Veeva Systems has your attention after this earnings move and its rich 45.2x P/E, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and watch how the thesis develops. Once you decide to build or adjust a position, keep on top of what matters most with the Portfolio Command Center that filters market noise into focused, portfolio specific alerts. Round out your view by tapping into the Community and seeing how other investors are thinking about Veeva Systems over time. This way you uncover potential catalysts and risks early and give yourself a better chance of staying a step ahead of the market.

Seeking Alternatives Beyond Veeva Systems?

Fresh opportunities do not wait forever. New themes gather momentum, prices move, and the cleanest entries get caught by early movers. Scan these curated ideas before the crowd and act now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.